Minimally Invasive Surgery is Associated with Improved Outcomes Compared to Open Craniotomy with Clot Evacuation after Spontaneous Intracerebral Hemorrhage in the AHA Get With The Guidelines Registry
Abstract Body: Introduction: Data are lacking on outcomes of minimally invasive surgery (MIS), an emerging surgical treatment for spontaneous intracerebral hemorrhage (ICH), compared to conventional open craniotomy with clot evacuation. We therefore sought to evaluate ICH outcomes after MIS vs conventional clot evacuation in a real-world, nationally representative US cohort. Methods: We performed a retrospective cohort study of patients with ICH from 2011-2021 in the Get With The Guidelines-Stroke registry. The exposure was the type of surgery, classified as open craniotomy with clot evacuation versus MIS (either endoscopic surgical evacuation or stereotactic evacuation with fibrinolytic therapy). The primary outcome was in-hospital mortality, and secondary outcomes included discharge disposition, ambulatory status at discharge, and modified Rankin score at discharge. Using overlap propensity matching, we matched patients with MIS versus open craniotomy on age, sex, race, NIH Stroke Scale, prior antithrombotic therapy, external ventricular drain use, and withdrawal of care. The overlap weighting creates exact balance on the mean of every measured covariate when the propensity score is estimated by logistic regression, and therefore, mimics the attributes of a clinical trial. Each MIS patient was matched with multiple patients who received open craniotomy, based on the propensity score. Logistic regression was used to study the relationship of the type of surgery with outcomes. Pre-specified subgroup analyses were stratified by age, sex, race, NIHSS, EVD use, and annual ICH volume. Results: Among 555,964 patients with ICH, MIS was performed in 703 patients (330 had stereotactic surgery and 373 had endoscopic surgery) and open craniotomy was performed in 7067 patients. In the matched cohort, in-hospital deaths occurred in 60/446 (13.5%) with MIS and 648/3675 (17.6%) with open craniotomy. In regression analyses, MIS was associated with lower odds of in-hospital mortality (aOR, 0.7; CI, 0.5-0.9), unfavorable discharge (aOR, 0.7; CI, 0.6-0.9), and higher odds of discharge to rehabilitation (aOR, 1.3; CI, 1.1-1.5), but not with functional outcomes (Table). In pre-specified subgroup analyses, lower mortality was noted with MIS in older patients and men (Figure). Conclusions: In a large, diverse US cohort of ICH patients, MIS was associated with lower odds of in-hospital mortality and better discharge disposition compared to open craniotomy with clot evacuation.
Murthy, Santosh
( WEILL CORNELL MEDICINE
, New York
, New York
, United States
)
Falcone, Guido
( YALE UNIVERSITY SCHOOL OF MEDICINE
, New Haven
, Connecticut
, United States
)
Payabvash, Sam
( YALE UNIVERSITY SCHOOL OF MEDICINE
, New Haven
, Connecticut
, United States
)
Ziai, Wendy
( JOHNS HOPKINS UNIV NEURO CRITICAL
, Baltimore
, Maryland
, United States
)
Knopman, Jared
( Weill Cornell Medical College
, New York
, New York
, United States
)
Matouk, Charles
( Yale University
, New Haven
, Connecticut
, United States
)
Mocco, J
( Mount Sinai Health System
, New York
, New York
, United States
)
Kamel, Hooman
( Weill Cornell Medicine
, New York
, New York
, United States
)
Sheth, Kevin
( YALE UNIVERSITY SCHOOL OF MEDICINE
, New Haven
, Connecticut
, United States
)
Zhang, Cenai
( Weill Cornell Medicine
, New York
, New York
, United States
)
Garton, Andew
( WEILL CORNELL MEDICINE
, New York
, New York
, United States
)
Mac Grory, Brian
( Duke University Hospital
, CARY
, North Carolina
, United States
)
Shah, Shreyansh
( Duke University Hospital
, CARY
, North Carolina
, United States
)
Fonarow, Gregg
( UCLA MEDICAL CENTER
, Los Angeles
, California
, United States
)
Schwamm, Lee
( Yale School of Medicine
, New Haven
, Connecticut
, United States
)
Bhatt, Deepak
( Mount Sinai Health System
, New York
, New York
, United States
)
Smith, Eric
( UNIVERSITY OF CALGARY
, Calgary
, Alberta
, Canada
)
Author Disclosures:
Santosh Murthy:DO NOT have relevant financial relationships
| Guido Falcone:DO NOT have relevant financial relationships
| Sam Payabvash:DO NOT have relevant financial relationships
| Wendy Ziai:DO NOT have relevant financial relationships
| Jared Knopman:DO NOT have relevant financial relationships
| Charles Matouk:DO have relevant financial relationships
;
Consultant:Penumbra:Active (exists now)
; Consultant:Navigantis:Active (exists now)
; Consultant:Hybernia:Active (exists now)
; Consultant:Microvention:Active (exists now)
; Consultant:Silk Road Medical:Active (exists now)
| J Mocco:DO have relevant financial relationships
;
Consultant:Viseon, Endostream, RIST, Synchron, Perflow, Viz.ai, CVAid, Imperative Care, Mendaera.:Active (exists now)
; Research Funding (PI or named investigator):National/International PI/Co-PI: INVEST (PI), COMPASS (Co-PI), THERAPY (PI), FEAT (PI), POSITIVE (Co-PI) COAST (Co-PI) PHIL (Co-PI) NIH: NIH: OTA STEP Platform (MPI), StrokeNet U01 (PI) 1 PCORI: TESTED Award (Co-PI):Active (exists now)
; Ownership Interest:Imperative Care, Endostream, Echovate, Viseon, BlinkTBI, Serenity, NTI Managers, RIST, Viz.ai, Synchron, Songbird, Tulavi, Vastrax, Neurolutions, Sim&Cure, Bendit, Myra Medical, Q’Apel, Instylla, Adona, Tulavi, Radical, E8, Borvo, Spinaker, Mendaera.:Active (exists now)
| Hooman Kamel:DO have relevant financial relationships
;
Other (please indicate in the box next to the company name):Financial disclosures for Hooman Kamel: a PI role in the ARCADIA trial, which received in-kind study drug from the BMS-Pfizer Alliance for Eliquis and ancillary study support from Roche Diagnostics; a Deputy Editor role for JAMA Neurology; clinical trial steering/executive committee roles for the STROKE-AF (Medtronic), LIBREXIA-AF (Janssen), and LAAOS-4 (Boston Scientific) trials; consulting or endpoint adjudication committee roles for AbbVie, AstraZeneca, Boehringer Ingelheim, and Novo Nordisk; and household ownership interests in TETMedical, Spectrum Plastics Group, and Ascential Technologies.:Active (exists now)
| Kevin Sheth:DO NOT have relevant financial relationships
| Cenai Zhang:DO NOT have relevant financial relationships
| Andew Garton:No Answer
| Brian Mac Grory:DO have relevant financial relationships
;
Research Funding (PI or named investigator):National Institutes of Health:Active (exists now)
; Research Funding (PI or named investigator):American Heart Association:Active (exists now)
| Shreyansh Shah:DO NOT have relevant financial relationships
| Gregg Fonarow:DO NOT have relevant financial relationships
| Lee Schwamm:DO have relevant financial relationships
;
Consultant:genentech:Active (exists now)
; Advisor:Penumbra:Past (completed)
; Consultant:medtronic:Active (exists now)
| Deepak Bhatt:DO have relevant financial relationships
;
Advisor:Angiowave, Bayer, Boehringer Ingelheim, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, High Enroll, Janssen, Level Ex, McKinsey, Medscape Cardiology, Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Stasys:Active (exists now)
; Other (please indicate in the box next to the company name):Honoraria cont: Journal of the American College of Cardiology (Guest Editor; Associate Editor), K2P (Co-Chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Oakstone CME (Course Director, Comprehensive Review of Interventional Cardiology), Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), WebMD (CME steering committees), Wiley (steering committee);:Active (exists now)
; Other (please indicate in the box next to the company name):Trustee: American College of Cardiology; Unfunded Research: FlowCo.:Active (exists now)
; Other (please indicate in the box next to the company name):Site Co-Investigator: Abbott, Biotronik, Boston Scientific, CSI, Endotronix, St. Jude Medical (now Abbott), Philips, SpectraWAVE, Svelte, Vascular Solutions;:Active (exists now)
; Royalties/Patent Beneficiary:Royalties: Elsevier (Editor, Braunwald’s Heart Disease);:Active (exists now)
; Research Funding (PI or named investigator):Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Alnylam, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CinCor, Cleerly, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Otsuka, Owkin, Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, Youngene, 89Bio;:Active (exists now)
; Royalties/Patent Beneficiary:Sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women's Hospital who assigned to Lexicon; neither I nor Brigham and Women's Hospital receive any income from this patent);:Active (exists now)
; Other (please indicate in the box next to the company name):Other: Clinical Cardiology (Deputy Editor);:Active (exists now)
; Other (please indicate in the box next to the company name):American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), CSL Behring (AHA lecture), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology),:Active (exists now)
; Other (please indicate in the box next to the company name):Data Monitoring Committees: Acesion Pharma, Assistance Publique-Hôpitaux de Paris, Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (Chair, PEITHO trial), Cleveland Clinic, Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo; for the ABILITY-DM trial, funded by Concept Medical; for ALLAY-HF, funded by Alleviant Medical), Novartis, Population Health Research Institute; Rutgers University (for the NIH-funded MINT Trial);:Active (exists now)
; Consultant:Broadview Ventures, GlaxoSmithKline, Hims, SFJ, Youngene:Active (exists now)
; Individual Stocks/Stock Options:Board of Directors: Angiowave (stock options), Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock):Active (exists now)
; Other (please indicate in the box next to the company name):Board of Directors: American Heart Association New York City, Angiowave (stock options), Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock):Active (exists now)
| Eric Smith:DO NOT have relevant financial relationships
Menegat Brenda Luana Rocha Soares, Menegaz De Almeida Artur, Kelly Francinny, A De Moraes Francisco Cezar, Menegat Ana Luiza Rocha Soares, Rocha Dantas Clara, Rachas Reis Mariana, De Souza Wagner Pedro, Simões Bárbara, Alves Mylena, Matheus Gustavo Tadeu, Bezerra Ian
Lusk Jay, Bhatt Deepak, Saver Jeffrey, Mac Grory Brian, Brown Scott, Hassan Ameer, Albers Gregory, Fonarow Gregg, Schwamm Lee, Messe Steven, Smith Eric, Hasan David